Flower City Capital Invests $254,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Flower City Capital purchased a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 3,000 shares of the company's stock, valued at approximately $254,000.

Several other hedge funds also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. bought a new position in Axsome Therapeutics during the second quarter valued at about $27,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Axsome Therapeutics in the 2nd quarter valued at about $47,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Axsome Therapeutics by 22.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company's stock worth $156,000 after purchasing an additional 318 shares during the last quarter. Moors & Cabot Inc. bought a new stake in shares of Axsome Therapeutics in the 3rd quarter worth approximately $200,000. Finally, Whalen Wealth Management Inc. acquired a new stake in Axsome Therapeutics during the third quarter valued at approximately $236,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. HC Wainwright reaffirmed a "buy" rating on shares of Axsome Therapeutics in a report on Tuesday, December 31st. Robert W. Baird upped their target price on Axsome Therapeutics from $112.00 to $116.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. Truist Financial lifted their price target on Axsome Therapeutics from $150.00 to $180.00 and gave the stock a "buy" rating in a research note on Monday, January 13th. StockNews.com raised shares of Axsome Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th. Finally, Needham & Company LLC restated a "buy" rating and set a $133.00 price target on shares of Axsome Therapeutics in a report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, Axsome Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $130.69.

Axsome Therapeutics Price Performance

Shares of Axsome Therapeutics stock traded down $1.76 during midday trading on Monday, hitting $91.93. 808,350 shares of the company were exchanged, compared to its average volume of 724,302. The firm has a 50 day simple moving average of $92.27 and a 200-day simple moving average of $89.53. Axsome Therapeutics, Inc. has a 52 week low of $64.11 and a 52 week high of $105.00. The firm has a market cap of $4.45 billion, a P/E ratio of -14.08 and a beta of 1.04. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The business had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. During the same quarter in the prior year, the firm earned ($1.32) EPS. Research analysts forecast that Axsome Therapeutics, Inc. will post -4.61 earnings per share for the current year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.